ARTL
NASDAQArtelo Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.14+0.01 (+0.89%)
07:00 PM07:45 PM
News · 26 weeks70+83%
2026-01-182026-07-12
Mix2790d
- SEC Filings15(56%)
- Other12(44%)
Latest news
25 items- SECArtelo Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form DEFA14A filed by Artelo Biosciences Inc.DEFA14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain ConditionsSOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced new data supporting the therapeutic potential of ART26.12, its proprietary and selective fatty acid binding protein 5 (FABP5) inhibitor, as a novel product candidate for the treatment of osteoarthritis (OA) pain. Martin Kaczocha, Ph.D., Professor of Anesthesiology at Stony Brook University, New York, presented the research results at the International Cannabinoid Re
- SECSEC Form DEFA14A filed by Artelo Biosciences Inc.DEFA14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026SOLANA BEACH, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today reminds shareholders to vote their shares in advance of the Company's Annual Meeting of Shareholders, scheduled to be held virtually on July 17, 2026. The Company is asking all shareholders of record, regardless of the number of shares owned, to participate by submitting their proxy as soon as possible. Shareholders who have already voted are thanked for their participation. Those who have not yet vot
- PRArtelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral NeuropathyExpands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer Findings suggest broader utility in cancer supportive care, building on interim findings from CAReS Phase 2 clinical study which demonstrated improvements in body weight, lean body mass and activity levels SOLANA BEACH, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced promising results from nonc
- SECSEC Form DEFA14A filed by Artelo Biosciences Inc.DEFA14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord InjurySOLANA BEACH, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced positive new data from a preclinical study in neuropathic pain from spinal cord injury. The findings are being presented today at the International Cannabinoid Research Society 2026 Annual Symposium in Dijon, France and the Company believes the results support the broad therapeutic potential of ART26.12, Artelo’s proprietary clinical stage selective fatty acid bindin
- PRArtelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026SOLANA BEACH, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced results utilizing multi-omics analyses that identified a potential mechanistic links across disease models with ART26.12, the Company’s lead selective Fatty Acid Binding Protein 5 (FABP5) inhibitor that was presented at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium being held in Dijon, France. Artelo researchers evaluated datasets generated across multiple diseas
- PRArtelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research Advancing Development of Novel Biomarkers SOLANA BEACH, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced two presentations of clinical and translational research findings supporting the development of ART26.12, the Company's proprietary selective fatty acid binding protein 5 (FABP5) inhibitor, at the International Cannabinoid Research So
- SECSEC Form PRER14A filed by Artelo Biosciences Inc.PRER14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development SuccessSOLANA BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces that Myles Osborn, Lead Medicinal Chemist at Artelo, is delivering an oral presentation today highlighting encouraging metabolite identification and profiling data from the Company's lead FABP inhibitor candidate, ART26.12, during the 7th RSC-BMCS/DMDG New Perspectives in DMPK and Medicinal Chemistry Conference, held at the Burlington House in London. The presentation fe
- SECSEC Form DEFA14A filed by Artelo Biosciences Inc.DEFA14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form DEF 14A filed by Artelo Biosciences Inc.DEF 14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECArtelo Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form PRE 14A filed by Artelo Biosciences Inc.PRE 14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form 424B5 filed by Artelo Biosciences Inc.424B5 - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form EFFECT filed by Artelo Biosciences Inc.EFFECT - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form 424B5 filed by Artelo Biosciences Inc.424B5 - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECArtelo Biosciences Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form SCHEDULE 13G filed by Artelo Biosciences Inc.SCHEDULE 13G - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
- SECSEC Form 10-Q filed by Artelo Biosciences Inc.10-Q - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial ResultsSOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the quarter ended March 31, 2026, and outlined upcoming milestones across its portfolio. Business Highlights ART26.12 Progressing through Phase 1 studies: Following positive first-in-human Phase 1 single ascending dose and preliminary food-effect data with ART26.12, Artelo continues preparatio
- SECAmendment: SEC Form S-3/A filed by Artelo Biosciences Inc.S-3/A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form S-3 filed by Artelo Biosciences Inc.S-3 - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
ARTL FAQ
6 questionsWhat does Artelo Biosciences Inc. do?
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for...Where does ARTL stock trade?
Artelo Biosciences Inc. (ARTL) is listed on NASDAQ.What sector and industry is ARTL in?
Artelo Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ARTL?
Artelo Biosciences Inc. has had 2 recent analyst actions on file. The most recent action was from D. Boral Capital: Buy with a $2000.00 price target on 2025-07-08. Recent price targets range from $400.00 to $2000.00.What companies are similar to ARTL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ARTL side-by-side with any of them on Quantisnow.How can I track ARTL on Quantisnow?
Quantisnow aggregates Artelo Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARTL to receive live email and push alerts on every new disclosure.